Düll M, Kremer A (2020)
Publication Type: Journal article
Publication year: 2020
Book Volume: 19
Pages Range: 86-95
Journal Issue: 2
DOI: 10.1007/s11901-020-00517-x
Purpose of Review: Chronic pruritus represents a burdensome symptom in cholestatic liver disease. This review recommends a stepwise therapeutic approach, alongside with providing information on epidemiology, pathophysiology, and novel drug targets. Recent Findings: Current epidemiological data emphasize chronic itch as a major symptom in immune-mediated liver diseases such as primary biliary cholangitis affecting up to 70% of patients with a significant number suffering from long-lasting and severe pruritus. κ-opioid receptor (KOR) agonists, PPAR agonists, and ileal bile acid transporter (IBAT) inhibitors are currently investigated for their anti-pruritic efficacy in clinical trials. Future therapies may target the autotaxin-lysophosphatidic acid-axis or the Mas-related GPCR MRGPRX4. Summary: Cholestatic pruritus still remains a challenging symptom for patients and physicians. Using a stepwise approach including cholestyramine, rifampicin, bezafibrate, naltrexone, and sertraline, pruritus is often adequately manageable. KOR agonists and IBAT inhibitors are currently the most promising anti-pruritic drugs for cholestatic pruritus in development.
APA:
Düll, M., & Kremer, A. (2020). Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. Current Hepatology Reports, 19(2), 86-95. https://doi.org/10.1007/s11901-020-00517-x
MLA:
Düll, Miriam, and Andreas Kremer. "Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease." Current Hepatology Reports 19.2 (2020): 86-95.
BibTeX: Download